RecruitingNCT07146113
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian Federation
A Multicentre Observational Study on Treatment Approaches and Biomarkers in de Novo Metastatic Hormone Sensitive Prostate Cancer in Russian Federation
Sponsor
AstraZeneca
Enrollment
400 participants
Start Date
Jun 30, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
A multicentre observational study on treatment approaches and biomarkers in de novo metastatic hormone sensitive prostate cancer in Russian Federation
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria7
- Male patients aged ≥ 18 years old;
- Signed ICF, including consent for FFPE tumor tissue sample testing;
- De novo histologically confirmed high-aggressive (Gleason 8-10) mPC;
- Diagnosis of mPC (metastatic prostate cancer) within 2 years prior to inclusion;
- Availability of source medical documentation;
- Presence of biopsy FFPE tumor tissue sample, obtained as part of standard clinical practice, which will be used for biomarker testing;
- Unknown HRRm status.
Exclusion Criteria1
- \. Participation in any interventional trial since the mPC diagnosis.
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07146113
Related Trials
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
NCT070271241 location
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location